Prolactinomas in male and female patients: A comparative clinicopathologic study

被引:67
作者
Calle-Rodrigue, RDP
Giannini, C
Scheithauer, BW
Lloyd, RV
Wollan, PC
Kovacs, KT
Stefaneanu, L
Ebright, AB
Abboud, CF
Davis, DH
机构
[1] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Biostat Sect, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Mayo Med Sch, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Div Endocrinol Metab Nutr & Internal Med, Rochester, MN 55905 USA
[5] Mayo Clin & Mayo Fdn, Dept Neurol Surg, Rochester, MN 55905 USA
[6] St Michaels Hosp, Dept Pathol, Toronto, ON M5B 1W8, Canada
关键词
D O I
10.4065/73.11.1046
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To explore the basis of the gender-based differences in endocrine and surgical findings in patients with prolactinoma (prolactin cell adenoma) as well as in their clinical outcome. Material and Methods: In young or reproductive-age female patients, older women (beyond 40 years of age), and male patients, are systematically studied the following factors: operative and endocrine features (tumor size, invasiveness, preoperative serum prolactin level, and biochemical outcome), specific biologic variables (mitotic index, MIB-1 labeling index, and p27 immunoreactivity), and hormone receptor status (estrogen and progesterone receptor proteins as well as dopamine D-2 receptor messenger RNA). Results: Of the various factors assessed, the preoperative prolactin level and MIB-1 labeling index were lower in young female patients in comparison with older female and Particularly male patients. Hormone levels were also positively associated with mitotic activity as well as the MIB-1 labeling index. Although invasion was infrequent in microadenomas of young female patients, no statistically significant differences in tumor size or invasiveness were noted among the three patient groups. Absence of differences in invasiveness may, in part, be explained by artifacts of case selection. Conclusion: The basis for the observed differences in proliferative activities in tumors of the three study groups is not readily apparent but may reflect differences in the endocrine milieu or the effect of sex steroid hormone receptors, tumoral vascularity, or specific growth factors.
引用
收藏
页码:1046 / 1052
页数:7
相关论文
共 38 条
  • [31] Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody
    Thapar, K
    Kovacs, K
    Scheithauer, BW
    Stefaneanu, L
    Horvath, E
    Pernicone, PJ
    Murray, D
    Laws, ER
    [J]. NEUROSURGERY, 1996, 38 (01) : 99 - 106
  • [32] THAPAR K, 1995, PRINCIPLES PRACTICE, P103
  • [33] P27, A NOVEL INHIBITOR OF G1 CYCLIN-CDK PROTEIN-KINASE ACTIVITY, IS RELATED TO P21
    TOYOSHIMA, H
    HUNTER, T
    [J]. CELL, 1994, 78 (01) : 67 - 74
  • [34] PROLACTINOMAS
    VANCE, ML
    THORNER, MO
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1987, 16 (03) : 731 - 753
  • [35] VONWERDER K, 1982, FRONT NEUROENDOCRIN, V7, P123
  • [36] VONWERDER K, 1982, EXCERPTA MED INT C S, V584, P175
  • [37] NATURAL-HISTORY OF MICROPROLACTINOMAS - 6-YEAR FOLLOW-UP
    WEISS, MH
    TEAL, J
    GOTT, P
    WYCOFF, R
    YADLEY, R
    APUZZO, MLJ
    GIANNOTTA, SL
    KLETZKY, O
    MARCH, C
    [J]. NEUROSURGERY, 1983, 12 (02) : 180 - 183
  • [38] DOPAMINE, THE DOPAMINE D2-RECEPTOR AND PITUITARY-TUMORS
    WOOD, DF
    JOHNSTON, JM
    JOHNSTON, DG
    [J]. CLINICAL ENDOCRINOLOGY, 1991, 35 (06) : 455 - 466